Merck

Showing 15 posts of 363 posts found.

shutterstock_38078521

Apitope reclaims multiple sclerosis treatment from Merck after 7 years

October 17, 2016
Sales and Marketing ATX-MS-1467, Apitope, Merck, multiple sclerosis

Apitope has announced it has reclaimed the global rights to its multiple sclerosis (MS) treatment ATX-MS-1467 from Merck for the …

msd_merck_night_building

MSD’s Keytruda twice as successful against standard therapy for lung cancer

October 10, 2016
Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda

MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …

1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …

Merck elects Isabel De Paoli as CSO

September 27, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CSO, Merck, appointment

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …

Merck elects Isabel De Paoli as CSO

September 26, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, appointment

German pharma firm Merck has appointed Isabel De Paoli to the position of chief science officer in addition to her …

images

Roche’s Ocrevus more effective than Merck’s Rebif, company claims

September 14, 2016
Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis

Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …

merck_and_co

FDA to review MSD’s Keytruda as a first-line lung cancer treatment

September 7, 2016
Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo

The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …

merck_and_co

MSD drops osteoporosis trial drug due to stroke risk

September 5, 2016
Research and Development, Sales and Marketing MSD, Merck, Odanacatib, osteoporosis, stroke

MSD, known as Merck in the US and Canada, has announced that it has finally decided to discontinue the development …

merck_incweb

MSD joins Medivation race, says reports

August 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover

MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …

mr058666-web

Merck Q2 results beat analyst estimates

August 4, 2016
Medical Communications, Sales and Marketing Merck, financial results

Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, …

merck_incweb

MSD scores EU approval for Keytruda in lung cancer

August 3, 2016
Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …

merckwindow

400 current and former employees join sexual discrimination lawsuit against MSD

July 25, 2016
Research and Development, Sales and Marketing MSD, Merck, discrimination, lawsuit

Over 400 women have come forward to join a $250 million gender bias class action against MSD, called Merck in …

merckwindow

MSD faces delay in C. diff drug approval as FDA requests more data

July 22, 2016
Medical Communications, Research and Development C diff, FDA, MSD, Merck

MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. …

msd

UK medical charity sells part of interest in MSD’s Keytruda for $150 million

July 15, 2016
Research and Development, Sales and Marketing MSD, Merck, keytruda

UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …

The Gateway to Local Adoption Series

Latest content